WBA:NSD-Walgreens Boots Alliance, Inc (USD)

COMMON STOCK | Pharmaceutical Retailers | NSD

Last Closing Price

USD 47.49

Change

+0.66 (+1.41)%

Market Cap

USD 40.78B

Volume

4.09M

Avg Analyst Target

USD 54.67 (+15.11%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services. As of August 31, 2020, this segment operated 9,021 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies. The Retail Pharmacy International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as through boots.com and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 550 optical practices, including 165 on a franchise basis. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in the United Kingdom, Germany, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CVLB Conversion Labs, Inc

N/A

USD0.70B N/A N/A
PETS PetMed Express, Inc

+0.33 (+1.11%)

USD0.64B 23.25 14.54
YI 111, Inc

+0.30 (+4.87%)

USD0.49B N/A N/A
GNLN Greenlane Holdings, Inc

-0.05 (-1.47%)

USD0.06B 41.05 N/A
CJJD China Jo-Jo Drugstores, Inc

-0.04 (-4.25%)

USD0.03B 69.00 42.28
BIMI BIMI International Medical Inc

-0.05 (-4.24%)

USD0.03B 92.50 21.02

ETFs Containing WBA

Symbol Name Weight Mer Price(Change) Market Cap
DJD Invesco Dow Jones Industr.. 0.00 % 0.07 %

+0.39 (+0.88%)

USD0.17B
ESGS Columbia ETF Trust I - Co.. 0.00 % 0.35 %

+0.34 (+0.94%)

USD5.42M
FMK First Trust Mega Cap Alph.. 0.00 % 0.70 %

N/A

USD0.02B
IBDK iShares iBonds Dec 2019 T.. 0.00 % 0.10 %

N/A

USD0.63B
RDIV Invesco S&P Ultra Dividen.. 0.00 % 0.39 %

+0.55 (+1.38%)

USD0.77B
SDY SPDR S&P Dividend ETF 0.00 % 0.35 %

+1.15 (+0.94%)

USD19.67B
VVL:CA Vanguard Global Value Fac.. 0.00 % 0.38 %

+0.62 (+1.62%)

USD0.19B
ICAN SerenityShares Impact ETF 0.00 % 0.50 %

N/A

USD4.27M
IVFVC Ivy Focused Value NextSha.. 0.00 % 0.78 %

N/A

USD8.39M
UDVD:LSE SSgA SPDR ETFs Europe I P.. 0.00 % 0.35 %

-0.02 (-0.02%)

USD2.77B
VVAL:LSE Vanguard Global Value Fac.. 0.00 % 0.00 %

N/A

USD0.24B
SPYD:F SSgA SPDR ETFs Europe I P.. 0.00 % 0.35 %

+0.41 (+0.71%)

USD3.21B
SPYD:XETRA SSgA SPDR ETFs Europe I P.. 0.00 % 0.35 %

+0.13 (+0.23%)

USD3.21B

Market Performance

  Market Performance vs.
Industry/Classification (Pharmaceutical Retailers)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.08% 100% A+ 68% D+
Dividend Return 2.34% 100% A+ 73% C
Total Return 21.43% 100% A+ 69% D+
Trailing 12 Months  
Capital Gain 16.03% 100% A+ 39% F
Dividend Return 4.57% 100% A+ 71% C-
Total Return 20.60% 100% A+ 41% F
Trailing 5 Years  
Capital Gain -40.53% 67% D+ 15% F
Dividend Return 10.72% 50% F 41% F
Total Return -29.80% 67% D+ 17% F
Average Annual (5 Year Horizon)  
Capital Gain -12.55% 33% F 7% F
Dividend Return 2.72% 50% F 68% D+
Total Return -9.83% 33% F 8% F
Risk Return Profile  
Volatility (Standard Deviation) 16.82% 100% A+ 83% B
Risk Adjusted Return -58.47% 33% F 4% F
Market Capitalization 40.78B 100% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Pharmaceutical Retailers)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.83 100% A+ 49% F
Price/Book Ratio 1.85 67% D+ 64% D
Price / Cash Flow Ratio 7.44 33% F 43% F
EV/EBITDA 16.52 75% C 49% F
Management Effectiveness  
Return on Equity 10.02% 83% B 71% C-
Return on Invested Capital 1.60% 83% B 57% F
Return on Assets 2.54% 83% B 68% D+
Debt to Equity Ratio 59.13% 25% F 35% F
Technical Ratios  
Short Ratio 1.90 83% B 60% D-
Short Percent 1.87% 83% B 65% D
Beta 0.47 67% D+ 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.